CVS Health Corporation (CVS)

Total return at 5 years: 20.7%/year = 18.5% appreciation + 2.2% dividend. The target price ($227) is ex-dividend; the $15 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $265 · Multiples $195) exceeds the market price ($97).

Today — with margin of safety: at $97 trades ~50.1% below its value discounted to today (~$195) — the wide discount we require (≥38%, equivalent to a ~15% annual return); the risk is covered by the margin, not the rate.

At 5 years — Muy infravalorado: the target price ($227) plus dividends yield above the required average return (10%) — the business compounds.

The bridge: the return at 5 years comfortably exceeds the risk-free rate (4.5%) — and the discount reaches the required margin of safety.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($97) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-12.2%/year) than we project (5.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$7.3 bn of owner earnings in year 5 (vs ~$17.8 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on EBIT ajustado (suma de las partes). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

CVS is a sum-of-the-parts case: four segments of a different economic nature (Health Care Benefits is a health insurer that assumes medical risk via Aetna; Health Services is the CVS Caremark PBM plus value-based primary care; Pharmacy & Consumer Wellness is traditional retail pharmacy; Corporate/Other is a drag from legacy businesses in run-off). The sum of segment revenue (US$473.6bn in FY2025) exceeds consolidated revenue (US$402.1bn) by 17.8% because the three operating segments bill activity to each other (the PBM processes prescriptions dispensed by the retail pharmacy, the insurer pays its own pharmacy network) and those intersegment transactions are eliminated on consolidation — the 2Q2026 release itself states this explicitly, in note (a) of its segment reconciliation. It is not an extraction error: it is the business's vertical economics. That is why the valuation does not apply a single multiple to the consolidated figure: each segment is weighted by its share of terminal adjusted operating income and capitalized at ITS OWN multiple (managed care for insurance, pharmaceutical distribution for the PBM, specialty retail for the pharmacy). Year-0 uses the trailing-twelve-month adjusted operating result through June 2026 (US$16.36bn on revenue of US$415.09bn, 3.94% margin) instead of GAAP (US$8.29bn, 2.0%): the difference is almost entirely the US$5,725 million goodwill impairment charge at Oak Street Health (Health Care Delivery) recognized in 3Q2025 -within the TTM window-, plus acquisition intangible amortization and one-time legal charges that the company itself excludes from its adjusted operating result measure, the one its chief operating decision maker uses to evaluate segment performance. The base case margin path assumes a modest recovery (3.94% to 4.5% over five years) supported by the Health Care Benefits margin recovery plan that the August 2026 guidance itself confirms (the medical benefit ratio fell from 89.9% to 87.4% year over year in 2Q2026, and guided 2026 adjusted EPS was raised from US$7.30-7.50 to US$7.90-8.10), not an aggressive expansion: the business remains exposed to structural PBM margin compression and to regulatory pressure on Medicare Advantage that the 10-K itself describes as a trend it expects to continue. The resulting combined exit multiple (~14.3x in the base case) lands just above the floor of the managed care archetype band [14,20x], reflecting the uneven quality of the mix (risk-bearing insurance + low-margin distribution + competed retail) and the moat's eroding direction. There is no active buyback to model: the company paused buybacks in FY2025 and in the first half of 2026 (US$0 per the 2Q2026 cash flow statement) to prioritize debt reduction (US$3,287 million repaid in H1-2026), so the excess is redeployed into deleveraging and is not accumulated as cash nor modeled as a reduction in share count.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $227 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $97, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $227 in 5 years plus $15 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $195. Against the current market price ($97), the margin of safety is 50.1% (trades below the maximum → there is margin) and the total return at that price would be 20.7% annually.

• Entry multiple vs. band. The current adjusted EV/EBIT (~10.6x) trades below the floor of the managed care band (14-20x), consistent with the reading that the market has not yet priced in the magnitude of the guided margin recovery.
• Sum-of-the-parts vs. consolidated consistency. The sum-of-the-parts valuation captures the business's mixed nature (insurance, PBM, retail) better than a single multiple on the consolidated figure, which would blend very different economics.
• Sensitivity to the exit multiple. The base case uses a combined multiple just above the floor of the band, leaving little room for additional re-rating in the adverse scenario if the moat keeps eroding.
• Quality of the normalized base. Year-0 normalizes the adjusted operating result by excluding the goodwill impairment charge, declared and verified against the company's own non-GAAP reconciliation, not a generic estimate.
• Dividend yield. The dividend (US$2.66 annualized, ~2.7% yield at the current price) has been frozen since 2024, with no recent growth, though it is also not at risk of a cut given operating cash flow.
• Trading comparables. Comparable health insurers (UnitedHealth, Elevance, Humana, Cigna) trade today with compressed multiples versus their history on the same sector concern of margin compression in Medicare Advantage.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (106%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC vs. the 10% bar. Invested capital (US$125.2bn) is high relative to NOPAT generated; the consolidated return on capital sits below the 10% bar, reflecting the capital-intensive, regulatory-heavy nature of insurance and years of acquisitions (Oak Street, Signify, Aetna) that inflated invested capital without a proportional return yet.
• Cash conversion. TTM operating cash flow (US$14.78bn) comfortably exceeds TTM GAAP net income (US$4.89bn), partly because the GAAP result is still carrying the impact of the non-cash goodwill impairment.
• Quality of reported margin. The adjusted operating margin (3.94% TTM) excludes acquisition intangible amortization and non-recurring charges; GAAP (2.0%) is the unadjusted figure, and the gap between the two is material.
• Financial leverage. Total debt of US$61.4bn against equity of US$79.7bn, under active reduction (US$3,287 million repaid in H1-2026).
• Stock-based compensation. SBC amounts to just 0.2% of revenue and 6.1% of TTM free cash flow, well below the method's materiality threshold (15-20% of cash flow); no need to expense it separately from the operating result.
• Sensitivity to accounting estimates. The insurance business depends on the estimate of medical costs payable (claims reserve); in 2025 the company recognized premium deficiency reserves of US$448M and US$471M, evidence the estimate can miss on the adverse side.
• Predictability of results. GAAP results were highly volatile in 2022-2025 (net income of US$4.3bn to US$8.3bn to US$4.6bn to US$1.8bn) from non-recurring impairments and litigation; the adjusted result is more stable but still subject to medical benefit ratio volatility.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The volume driver differs by segment: in insurance it is medical membership × risk-adjusted per-capita premium (CMS pays capitation in Medicare Advantage and Part D); in the PBM it is managed prescriptions × margin per prescription (administrative fee + spread + drugmaker rebate share); in retail it is dispensed prescriptions × margin per prescription plus front-store retail sales × retail margin. Medical membership is falling while retail dispensed prescriptions accelerate, a mix that favors the lower relative-margin segment within the blend.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Revenue growth. Revenue growing ~7.4% year over year (TTM), with all three operating segments contributing positively in 2Q2026.
• Insured membership growth. Health Care Benefits medical membership is declining (27.1M to 26.0M between FY2024 and 2Q2026), from the exit from the individual (ACA) insurance markets business and commercial attrition.
• Retail volume growth. Dispensed prescriptions accelerate (+4.3% year over year in 2Q2026) from the incorporation of Rite Aid files, though part of it is inorganic rather than pure organic growth.
• Reinvestment runway. Capex (US$3.0bn TTM) is below depreciation and amortization (US$4.5bn TTM), a sign of a mature business with no large pending capital project.
• Available TAM. U.S. health spending keeps growing structurally on population aging and drug pricing, though CVS competes for a shrinking share of it via disintermediation.
• Geographic diversification. The business is essentially 100% domestic to the U.S., with no international diversification to cushion local regulatory risk.
• Backlog or contracted revenue. Not directly applicable: PBM contracts and insurance policies renew annually, with no multi-year backlog comparable to an infrastructure business.

• Revenue recurrence. Insurance premiums and multi-year PBM contracts give revenue visibility, though with annual renewal exposed to price competition.
• Product differentiation. The PBM and pharmacy business are largely commoditized on price; the real differentiation lies in scale and network, not in the product itself.
• Pricing power. Limited: the filing itself describes structural price compression in the PBM from demand for lower-cost clients.
• Operating leverage. Moderate: margin improves with volume in retail and the PBM, but the insurance segment has negative operating leverage when the medical benefit ratio rises.
• Recession behavior. Health demand is defensive (prescriptions and medical care are not discretionary), although the commercial insurance business loses membership when unemployment rises.
• Sector capital cycle. The PBM and health insurance sector draws growing regulatory scrutiny rather than new capital, which limits new entrants but also compresses existing margins.
• Relevance in 10 years. Demand for health care, pharmacy, and benefit management will keep existing; the question is what portion of the value chain CVS manages to retain against disintermediation (direct-to-consumer sales by drugmakers).

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• !Leverage (net debt / EBITDA)Net debt / EBITDA 2.3x
• !Interest coverage (EBIT / interest)5.3x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 106% of ROIC
• !Value creation (ROIC − 10% bar)+1pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.7x — no over-investment
• !Float / working capitalConsumes cash $1.1 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 0.2% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Current liquidity. Current assets (US$75.3bn) exceed current liabilities (US$87.0bn), below 1x, typical of an insurer with short-term claims liabilities offset by premiums collected in advance.
• Net leverage. Total debt of US$61.4bn against short-term cash and investments of US$14.0bn; net debt of ~US$47.5bn on equity of US$79.7bn.
• Leverage trend. Under active reduction: US$3,287 million of debt repaid in the first half of 2026, funded with operating cash flow.
• Interest coverage. TTM adjusted EBIT (US$16.4bn) covers TTM interest expense (~US$3.1bn) more than 5 times.
• Quality of insurance reserves. The company recognized additional premium deficiency reserves of US$448M (individual insurance markets, ACA) and US$471M (group Medicare Advantage) in 2025, evidence that medical cost estimates can require material correction.
• Maturity structure. The current portion of long-term debt (US$1.96bn) is manageable against TTM operating cash flow of US$14.8bn.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• CEO track record. David Joyner took over in October 2024 with the explicit mandate to recover Health Care Benefits margin; the raised August 2026 guidance is the first hard evidence the plan is working.
• Alignment of interests. No controlling shareholder or concentrated insider equity stake (less than 1% of the director and executive group individually); alignment depends on variable compensation, not direct skin in the game.
• Recent capital allocation. The full buyback pause in FY2025-2026 to prioritize debt repayment is a conservative and defensible decision given the leverage level, though it delays direct shareholder return.
• Candor in communication. The company explicitly acknowledges in its release the one-time factors behind the margin improvement (absence of the prior-year premium deficiency reserve) rather than attributing the entire improvement to operating execution.
• Acquisition track record. The Oak Street Health and Signify Health acquisitions (2023) resulted in the US$5,725 million goodwill impairment of 2025, evidence the price paid was not sustained by the expected operating performance.

• Motivated sellers: FY2025 GAAP results were sunk by a US$5,725 million goodwill impairment and US$1,220 million in legacy litigation charges, non-recurring items that punished reported earnings well below the business's cash-generation capacity.
• Missing buyers: the Health Care Benefits margin recovery, confirmed with hard data in the August 2026 guidance, has not yet shown through in the multiple — the market remains anchored to the 2024-2025 medical benefit ratio volatility.
• Overpunished recovery: the stock trades 12% below its 52-week high despite the company raising its adjusted earnings guidance two quarters in a row in 2026.

The source of the discount has a name and is verifiable in the company's own release: guided adjusted EPS for the year rose from US$7.30-7.50 to US$7.90-8.10 between the two most recent quarterly releases, while the stock price did not proportionally track that revision.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -1%/year (-6% total): the margin of safety protects the downside. The bull (+36%/year, +365% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Medical benefit ratio volatility. Premiums are set in advance and cannot be recovered within the period if medical costs rise; the company already recorded a combined US$919 million of premium deficiency reserves in 2025.
• Structural compression of the PBM margin. The 10-K itself describes price compression as a trend it expects to continue, not a one-time event, directly affecting the segment with the greatest weight in operating results (Health Services).
• Antitrust scrutiny over the vertical integration. Proposed state legislation seeks to directly ban licensing pharmacies affiliated with a PBM, attacking the structural pillar of the integrated model.
• Dependence on Medicare/Medicaid reimbursement. ~20% of consolidated revenue comes from the federal government (~79% of that via Medicare); the proposed 2027 Medicare Advantage payment rate shows a marked slowdown (2.54% versus 7.16% in 2026), and CMS announced retroactive RADV audits for 2018-2024.
• Deterioration of the Medicare Advantage star rating. The share of members in plans rated 4 stars or higher fell from 88% (2025 rating) to 81% (2026 rating), directly reducing CMS reimbursement bonuses.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: wide moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 5% at a multiple/growth of 2.1 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 9% (EBIT/EV) + ROIC 11% → brushes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -12% vs our 5%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -5%/yr, bull-scenario ceiling +34%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, eroding; sources: efficient scale, switching costs, intangibles, cost advantage, network effects → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -12%, within what we project (5%) — the story squares with the numbers.